scholarly journals Iodide transport and breast cancer

2015 ◽  
Vol 227 (1) ◽  
pp. R1-R12 ◽  
Author(s):  
Vikki L Poole ◽  
Christopher J McCabe
Keyword(s):  
Breast Cancer ◽  
Incidence Rates ◽  
Monocarboxylate Transporter ◽  
Sodium Iodide Symporter ◽  
Breast Cancer Patients ◽  
Iodide Transport ◽  
Malignant Breast ◽  
Breast Cells ◽  
Radioiodide Therapy ◽  
And Function

Breast cancer is the second most common cancer worldwide and the leading cause of cancer death in women, with incidence rates that continue to rise. The heterogeneity of the disease makes breast cancer exceptionally difficult to treat, particularly for those patients with triple-negative disease. To address the therapeutic complexity of these tumours, new strategies for diagnosis and treatment are urgently required. The ability of lactating and malignant breast cells to uptake and transport iodide has led to the hypothesis that radioiodide therapy could be a potentially viable treatment for many breast cancer patients. Understanding how iodide is transported, and the factors regulating the expression and function of the proteins responsible for iodide transport, is critical for translating this hypothesis into reality. This review covers the three known iodide transporters – the sodium iodide symporter, pendrin and the sodium-coupled monocarboxylate transporter – and their role in iodide transport in breast cells, along with efforts to manipulate them to increase the potential for radioiodide therapy as a treatment for breast cancer.

Quality of Life and Well-Being of Breast Cancer Patients

2020 ◽  
pp. 67-94
Author(s):  
Melisa Anderson ◽  
Dwayne Tucker ◽  
Fabian G. Miller ◽  
Kurt Vaz ◽  
Lennox Anderson-Jackson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Negative Impact ◽  
Well Being ◽  
Treatment Modalities ◽  
Physical Aspect ◽  
Breast Cancer Patients ◽  
Malignant Breast

Breast cancer is a disease in which there is increased proliferation of malignant breast cells. This disease is more likely to begin in the ducts or lobules rather than the connective tissue. Globally, breast cancer is the most regularly diagnosed cancer. It is also a leading cause of cancer-related mortality in females. While cancer of the breast affects the physical aspect of patients, it can also negatively impact the quality of life (QoL) of survivors. There is a dearth of information, especially in the last decade, on the negative impact of breast cancer and treatment modalities on the QoL of patients. This review of the literature will examine the QoL and well-being of breast cancer patients to present a current perspective on the topic. Major findings of past and present articles that have contributed to improving the care of breast cancer patients will be summarized and included.

scholarly journals Rho GTPases: Big Players in Breast Cancer Initiation, Metastasis and Therapeutic Responses

Cells ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 2167
Author(s):  
Brock Humphries ◽  
Zhishan Wang ◽  
Chengfeng Yang
Keyword(s):  
Breast Cancer ◽  
Membrane Trafficking ◽  
Rho Gtpases ◽  
Migration And Invasion ◽  
Breast Cancer Patients ◽  
Cancer Initiation ◽  
Cell Type Specific ◽  
And Function ◽  
Therapeutic Responses

Rho GTPases, a family of the Ras GTPase superfamily, are key regulators of the actin cytoskeleton. They were originally thought to primarily affect cell migration and invasion; however, recent advances in our understanding of the biology and function of Rho GTPases have demonstrated their diverse roles within the cell, including membrane trafficking, gene transcription, migration, invasion, adhesion, survival and growth. As these processes are critically involved in cancer initiation, metastasis and therapeutic responses, it is not surprising that studies have demonstrated important roles of Rho GTPases in cancer. Although the majority of data indicates an oncogenic role of Rho GTPases, tumor suppressor functions of Rho GTPases have also been revealed, suggesting a context and cell-type specific function for Rho GTPases in cancer. This review aims to summarize recent progresses in our understanding of the regulation and functions of Rho GTPases, specifically in the context of breast cancer. The potential of Rho GTPases as therapeutic targets and prognostic tools for breast cancer patients are also discussed.

Phenotype And Function Of Dendritic Cells Derived From Breast Cancer Patients

2010 ◽  
Vol 125 (2) ◽  
pp. AB14
Author(s):  
A.Y. Hancharou ◽  
L.P. Titov ◽  
L.A. Putyrski ◽  
Y.L. Putyrski ◽  
L.M. DuBuske
Keyword(s):  
Breast Cancer ◽  
Dendritic Cells ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
And Function

Bilateral breast cancer: a case study

2019 ◽  
Vol 19 (3) ◽  
pp. 305-308
Author(s):  
Rajanigandha Tudu ◽  
Anup Kumar ◽  
Rashmi Singh ◽  
Payal Raina
Keyword(s):  
Breast Cancer ◽  
Primary Breast Cancer ◽  
Breast Cancer Incidence ◽  
Bilateral Breast Cancer ◽  
Late Presentation ◽  
Incidence Rates ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Screening Guidelines ◽  
Cancer Management

AbstractBackground:Breast cancer is the most common cancer among females worldwide. Increasing breast cancer incidence rates, improved diagnosis and management modalities and growing life expectancy have resulted in increasing numbers of women at risk of developing contralateral primary breast cancer. Bilateral breast cancer can occur synchronously or metachronously.Material and methods:This study reports three cases of bilateral breast cancer patients treated at our oncology department between March 2018 and March 2019. The features of presentation, investigation, diagnosis and follow-up care are the highlights of this study.Results:Bilateral breast cancer was noted in three patients among the study population in the age group of 35 –55 years. Two of these patients had metachronous bilateral breast cancer, and one patient developed cancer in the second breast during the course of management. The second breast cancers differed histologically from primary breast cancer.Conclusion:Poor awareness on breast cancer care and the lack of national screening guidelines and programmes, and poor infrastructure, all contribute to late presentation and difficult breast cancer management. Proper history, clinical examination and imaging of opposite breast should be done to ensure adequate and timely management of bilateral breast cancer.

scholarly journals Prolactin receptor in breast cancer: marker for metastatic risk

2016 ◽  
Vol 57 (4) ◽  
pp. R153-R165 ◽  
Author(s):  
Carrie S Shemanko
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Prolactin Receptor ◽  
Osteoclast Formation ◽  
Receptor Signaling ◽  
Breast Cancer Patients ◽  
Receptor Isoforms ◽  
Receptor Biology ◽  
Metastatic Risk ◽  
And Function

Prolactin and prolactin receptor signaling and function are complex in nature and intricate in function. Basic, pre-clinical and translational research has opened up our eyes to the understanding that prolactin and prolactin receptor signaling function differently within different cellular contexts and microenvironmental conditions. Its multiple roles in normal physiology are subverted in cancer initiation and progression, and gradually we are teasing out the intricacies of function and therapeutic value. Recently, we observed that prolactin has a role in accelerating the time to bone metastasis in breast cancer patients and identified the mechanism by which prolactin stimulated breast cancer cell-mediated lytic osteoclast formation. The possibility that the prolactin receptor is a marker for metastasis, and specifically bone metastasis, is one that may have to be put into the context of the different variants of prolactin, different prolactin receptor isoforms and intricate signaling pathways that are regulated by the microenvironment. The more complete the picture, the better one can test biomarker identity and design clinical trials to test therapeutic intervention. This review will cover the recent advances and highlight the complexity of prolactin receptor biology.

scholarly journals Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and malignant breast tumors

2019 ◽  
Author(s):  
Mustafa Fadhil ◽  
Omar Abdul- Rasheed ◽  
Manwar Al-Naqqash
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Tumor ◽  
Healthy Subjects ◽  
Breast Tumors ◽  
Breast Cancer Patients ◽  
Cancer Tumor ◽  
Malignant Breast

Background: During tumor progression, circulating monocytes and macrophages are actively recruited into tumors where they alter the tumor microenvironment to accelerate tumor progression. In response to multiple microenvironmental signals from the tumor and stromal cells, macrophages change their functional phenotypes. Based on their function, macrophages are commonly classified into both, classical M1 and alternative M2 macrophages. M2-like tumor-associated macrophages promote breast tumor growth and survival, and may migrate into the peripheral blood. However, the level of circulating M2/M1-like monocyte ratio in the peripheral blood of breast cancer patients has not been yet clarified. Aim: To compare peripheral blood M2/M1 monocyte ratio among breast cancer patients, benign breast tumor patients and healthy subjects. Also, to investigate the role of peripheral blood M2/M1 monocyte ratio as a circulating breast cancer tumor marker and to asses the validity of this marker in differentiation between benign and malignant breast tumors. Methods: Flow cytometry technique was used to determine the peripheral blood M2/M1 monocyte ratio in three groups of subjects, i.e. 45 patients with breast cancer, 40 patients with benign breast tumor, and 40 healthy subjects as a control group. The results of carbohydrate antigen15-3 (CA15-3) determination were analyzed comparatively. Results: The peripheral blood M2/M1 monocyte ratio in patients with breast cancer (0.27±0.1) was significantly higher (P<0.001) than that in healthy subjects (0.07±0.05) and than in benign tumor subjects (0.08±0.04). The area under the receiver operating characteristic (ROC) curve of peripheral blood M2/M1 monocyte ratio determination was significantly higher (P≤0.001) than that of CA15-3 levels. Conclusion: M2/M1-like monocyte ratio is of a high diagnostic value for breast cancer and is a promising differentiating marker between benign and breast cancer tumor groups.

scholarly journals Racial Disparities in the Incidence, Breast Conserving Rate and Survival of Breast Cancer Patients Who Underwent Breast Conserving Surgery

2021 ◽  
Author(s):  
Shu Han ◽  
Jianjun Liu ◽  
Weifang Tang ◽  
Shengying Wang ◽  
Shikai Hong
Keyword(s):  
Breast Cancer ◽  
Racial Disparities ◽  
Cancer Incidence ◽  
White Women ◽  
Breast Cancer Incidence ◽  
Relative Survival ◽  
Breast Conserving Surgery ◽  
Incidence Rates ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival

Abstract Objective: In the current study, we aimed to provide a clear insight on the racial disparity of breast conserving rate (BCR) and survival in breast cancer after breast conserving surgery (BCS). Materials and Methods: Using data from the Surveillance, Epidemiology, and End Results program (SEER), we estimated breast cancer incidence rates and the rate of BCS by race in two periods (2000-2004 and 2013-2017). Relative survival analysis was based on patient-level data from 1998 to 2017. To be adjusted for baseline differences for different races, inverse probability weighting (IPW) models were stepwise performed.Results: From 2000-2004 to 2013-2017, both the breast cancer incidence (from 4.18 to 5.05 per 1000 white women) and the proportion of patients after BCS (from 55.5% to 59.9) were highest in whites than that of other races. Black individuals’ incidence (1.20 per 1000 black women or relatives 43.6% increased) and the BCR were increased most rapidly (6%) than other races. Asian or Pacific Islanders (APIs) were less likely to be diagnosed at a later stage and had the best prognosis than those of other races. After baselines fully adjusted, whites had the better Breast Cancer Specific Survival (BCSS) and Overall Survival (OS) than that of minorities (all p< 0.001).Conclusions: We identified the racial disparities of breast cancer incidence, BCR, and survival differences. We found increase trends of breast cancer incidence and BCR in minorities; however, we also identified the worse survival of minorities than that of whites, regardless of age, tumor stage, grade, and Luminal subtype.

scholarly journals ANALYSIS OF DOXORUBICIN AND DOXORUBICINOL IN DRIED BLOOD SPOT OF BREAST CANCER PATIENTS FOR MONITORING THE CARDIOTOXICITY OF DOXORUBICIN

2020 ◽  
pp. 21-25
Author(s):  
YAHDIANA HARAHAP ◽  
SABRINA NUR AMALIA ◽  
ALDHI ANARTA ◽  
RAMADHAN
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Gradient Elution ◽  
Ultra Performance Liquid Chromatography ◽  
Incidence Rates ◽  
Dried Blood Spot ◽  
Precipitation Method ◽  
Breast Cancer Patients ◽  
Acquity Uplc ◽  
Blood Spot

Objective: This study aimed to analyze doxorubicin and doxorubicinol levels in Dried Blood Spot (DBS) from 25 breast cancer patients who received doxorubicin in their therapeutic regiment. Methods: DBS samples were extracted by protein precipitation method and analyzed using Ultra Performance Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS), with the Acquity UPLC BEH C18 Waters chromatography column (2.1 x 100 mm x 1.7 μm). The mobile phase consisted of 0.1% acetic acid (eluent A) and acetonitrile (eluent B) with gradient elution; the flow rate was 0.15 ml/min and runtime, 7 min. This method was linear within the concentration range of 10–200 ng/ml for doxorubicin and 4–100 ng/ml for doxorubicinol. Result: The analysis results showed that doxorubicin levels were in the range of 11.01 ng/ml to 93.75 ng/ml and doxorubicinol was 5.80 ng/ml to 58.57 ng/ml. Conclusion: Cumulative doses of all patients were in the range of 49.11 mg/m2to 303.70 mg/m2, which have cardiomyopathy incidence rates<4%.

Presence of bone marrow micrometastasis (BMM) in breast cancer patients predicts a poor-prognosis pattern of first distant metastasis: Results from the pooled analysis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 567-567
Author(s):  
S. Braun ◽  
F. D. Vogl ◽  
K. Pantel
Keyword(s):  
Breast Cancer ◽  
Distant Metastasis ◽  
Poor Prognosis ◽  
Surrogate Marker ◽  
Disease Free Survival ◽  
Incidence Rates ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Metastatic Relapse ◽  
Visceral Metastases

567 Background: As a putative surrogate marker of ubiquitous distant metastasis, which is assessable both at initial diagnosis of breast cancer and during adjuvant therapy, BMM would be a valuable end-point marker for adjuvant clinical trials. Methods: Based on individual pt data of 4,686 breast cancer pts with a 10-year follow-up (median, 62 months), we analyzed distant disease-free survival (DDFS) of BMM+/BMM− pts, and looked specifically into sites of first metastatic relapse, expressed as bone metastasis-free (BFS), visceral metastasis-free (VFS), and multiple metastasis-free survival (MFS; i.e., simultaneous diagnosis of bone and visceral metastases). We performed Kaplan-Meier analysis and computed incidence rates (IR)/ incidence rate ratios (IRR) for the occurrence of metastasis at different sites. Results: BMM were detected in 1,432 (30.6%) of pts overall and significantly more often in pts with subsequent diagnosis of distant metastasis as compared to those who survived without metastases (48.5% vs. 26.0%, P<0.001). BMM+ pts had a significantly shorter DDFS than BMM- pts (IRR 2.36; 95%CI, 2.07–2.69; P<0.001). This was also true when we analyzed either bone (IRR 2.73; 95%CI, 2.27–3.29; P<0.001) or visceral metastases only (IRR, 2.48; 95%CI, 2.11–2.91; P<0.001). Among 952 pts with occurrence of distant metastasis, IR of such an event was 1.28-fold (95%CI, 1.12–1.46; P<0.001) higher in BMM+ pts than in BMM- pts. Among 462 BMM+ pts (but not among those 490 BMM- pts), IRs for MFS were significantly increased as compared to both VFS (IRR 1.72; 95%CI, 1.36–2.18; P<0.001) and BFS (IRR 1.85; 95%CI 1.21–2.06; P=0.001). IR for BFS of BMM+ patients (1.08; 95%CI 0.87–1.34) was not significantly increased over VFS. Conclusion: Our data provide conclusive evidence that presence of BMM predicts an early onset and a poor prognosis pattern of overt distant metastasis. With the similar likelihood of the occurrence of subsequent metastasis in bone and at visceral sites, BMM appears to be a marker of generalized tumor cell spread. No significant financial relationships to disclose.

scholarly journals Incidence of Breast Cancer in Eritrea: A Retrospective Study from 2011 to 2017

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Lidia B. Medhin ◽  
Lia A. Tekle ◽  
Daniel T. Fikadu ◽  
Danait B. Sibhatu ◽  
Samson F. Gebreyohans ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Incidence ◽  
Incidence Rates ◽  
Total Incidence ◽  
Breast Cancer Epidemiology ◽  
Icd 10 ◽  
Malignant Breast ◽  
Standard Rate ◽  
Low Prevalence

In Africa, breast cancer closely compares with cervical cancer as the most common malignancy affecting women and the incidence rates appear to be rising. Eritrea is experiencing a growing breast cancer problem, but little is presently known on tumor patterns, breast cancer epidemiology, and risk factors. The main objective of this study is to provide baseline data on breast cancer incidence in both sexes in Eritrea. This study was carried out retrospectively and quantitatively by collecting, abstracting, analyzing, coding, and interpreting data recorded in National Health Laboratory (NHL) using CanReg5 ver. 5.00.35. Extracting and classification of the tumor data was done using topography, morphology together with the ICD-10. To generate the incidence rate for the seven years the Eritrean population dataset was used from the population pyramid net for 2014. After we entered all the data from Pathology department in NHL, data was analyzed using the predetermined and developed built-in analysis tools of CanReg5 software and Microsoft Excel 2010. A total number of 9,403 pathology cases were recorded from 2011 to 2017. Out of these 1,497 cases were confirmed as cytology and histology of breast cases. From 1,497 confirmed breast cases in both sexes, the incidence of benign cases was higher than incidence of malignant cases with the case number of 1, 149, and 348, respectively. Out of the 1,497 cases, 1,447 (96.66%) were females; this included a total incidence cases of female benign and malignant breast cases 1,111 (76.78%), and 336 (23.22%), respectively. In both female and male age group the highest positive cases were found in the age greater than 85. The incidence age standard rate per 100,000 in females and male was 3.3 and 0.2, respectively. In sum, the age standardized incidence of breast cancer was relatively low. However, it is our opinion that the low prevalence may be due to low awareness and a highly centralized screening and diagnostic services. This limits access. Altogether, it is our opinion that breast cancer presents a burden to Eritrean ministry of health.

Sign in / Sign up

Export Citation Format

Share Document